With $20.7 Million Series A Cash, RaNA Seeks To Be A Groundbreaker In Long Non-Coding RNA Therapeutics

Biotech hopes to begin IND-enabling studies in 2013 and bring first candidate into the clinic in 2014 in a new field it believes will have applicability in numerous therapeutic areas.